Form 4 for SKYE Skye Bioscience, Inc.
Accepted 2022-11-15 00:00:00 ET · period of report 2022-11-10 · accession 0001516551-22-000047 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DI | 2022-11-15 | 2022-11-10 | SKYE | DHILLON PUNIT | CEO, Dir | A - Grant | — | +2.34M | 2.34M | New | — |
| D | 2022-11-15 | 2022-11-10 | SKYE | DHILLON PUNIT | CEO, Dir | A - Grant | — | +1.41M | 4.41M | +47% | — |
| DM | 2022-11-15 | 2022-11-10 | SKYE | DHILLON PUNIT | CEO, Dir | A - Grant | — | +1.56M | 487.5K | New | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-10 | A | A | 2,335,721 | — | 2,335,721 | I | — | — | (F1) The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). |
| 2 | Common | Common Stock | 2022-11-10 | A | A | 1,406,543 | — | 4,406,543 | D Trust | — | — | (F1) The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement, dated as of May 11, 2022 (as amended, the "Arrangement Agreement"). Pursuant to the terms of the Arrangement Agreement, each holder of EHT shares received 1.95 shares of company common stock for each EHT share (the "Exchange Ratio"). (F2) The shares are held by a trust for which the Reporting Person is a trustee and has voting and dispositive power over the shares. |
| 3 | Derivative | Stock Option (Right to Buy) | 2022-11-10 | A | A | 292,500 | — | 292,500 | D | $0.08 · — to 2025-08-03 | 292,500 Common Stock | (F3) The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. (F6) 8.33% of the options vested on the grant date of August 3, 2020. An additional 8.333% of the options vest on each monthly anniversary of the grant date. |
| 4 | Derivative | Stock Option (Right to Buy) | 2022-11-10 | A | A | 390,000 | — | 390,000 | D | $1.60 · — to 2024-04-03 | 390,000 Common Stock | (F3) The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. (F4) The options underlying this award are fully vested. |
| 5 | Derivative | Stock Option (Right to Buy) | 2022-11-10 | A | A | 390,000 | — | 390,000 | D | $0.11 · — to 2025-02-06 | 390,000 Common Stock | (F3) The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. (F5) Options will vest, or have vested, in equal installments on each of February 6, 2020, February 6, 2021, February 6, 2022, February 6, 2023. |
| 6 | Derivative | Stock Option (Right to Buy) | 2022-11-10 | A | A | 487,500 | — | 487,500 | D | $0.06 · — to 2025-04-27 | 487,500 Common Stock | (F3) The reporting person acquired these securities on November 10th, 2022, in exchange for the reporting person's securities of Emerald Health Therapeutics, Inc., which the company acquired by way of a plan of arrangement pursuant to the Arrangement Agreement. Pursuant to the terms of the Arrangement Agreement, each option to purchase EHT shares was exchanged into an option to purchase shares of company common stock, with the number of shares underlying each option (and the exercise price of such option) adjusted based on the Exchange Ratio. (F4) The options underlying this award are fully vested. |